Ralliant (NYSE:RAL) SVP Karen Bick Sells 2,530 Shares

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 2,530 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $46.50, for a total value of $117,645.00. Following the completion of the transaction, the senior vice president directly owned 42,652 shares of the company’s stock, valued at $1,983,318. The trade was a 5.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ralliant Stock Up 0.7%

RAL opened at $44.97 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84. The company has a market cap of $5.03 billion and a price-to-earnings ratio of 22.94. Ralliant Corporation has a one year low of $37.27 and a one year high of $57.02. The business’s fifty day moving average is $48.82 and its two-hundred day moving average is $46.72.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million during the quarter, compared to analysts’ expectations of $543.04 million. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s dividend payout ratio is presently 10.20%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RAL. Morgan Stanley restated an “overweight” rating and set a $45.00 target price on shares of Ralliant in a research report on Friday, February 6th. Weiss Ratings cut shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Truist Financial cut their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Oppenheimer reduced their target price on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, February 6th. Finally, Royal Bank Of Canada lowered their target price on Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $50.50.

Institutional Investors Weigh In On Ralliant

Several hedge funds have recently modified their holdings of RAL. Vanguard Group Inc. raised its position in shares of Ralliant by 10.7% in the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock valued at $637,995,000 after buying an additional 1,415,327 shares during the last quarter. Dodge & Cox lifted its stake in shares of Ralliant by 13.3% during the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock valued at $621,849,000 after buying an additional 1,434,376 shares during the period. Viking Global Investors LP acquired a new stake in Ralliant during the second quarter worth approximately $257,200,000. Millennium Management LLC grew its stake in Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after acquiring an additional 3,147,660 shares during the period. Finally, State Street Corp purchased a new stake in Ralliant in the 2nd quarter worth approximately $213,096,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.